Name: Avadel Pharmaceuticals plc (AVDL) Financial Statements
Creator: FinSpry

Avadel Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Avadel Pharmaceuticals plc income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	169.12	27.96	0.12	0.11	22.33	59.22	103.27
Cost of Revenue	15.28	0.85	-3.35	0.05	5.74	12.13	17.52
Gross Profit	153.84	27.12	3.46	0.06	16.59	47.09	85.75
Operating Expenses
Research & Development	15.20	13.26	20.70	17.10	20.44	32.92	39.33
Selling, General & Administrative	181.04	151.71	74.52	68.50	32.41	30.18	100.36
Operating Expenses	196.24	164.97	95.22	85.60	53.25	64.76	146.31
Operating Income	-42.40	-137.85	-95.22	-85.60	-36.66	-24.11	-60.55
Other Income/Expense
Interest Income	0.00	0.00	0.00	2.44	0.41	0.00	0.00
Interest Expense	10.83	9.89	12.34	-9.94	-12.99	0.00	10.62
Other Income/Expense	-6.68	-13.04	-3.88	-2.34	-47.86	1.99	-42.02
Income
Income Before Tax	-49.08	-160.78	-111.44	-93.15	-5.08	-38.58	-113.20
Income Tax Expense	-0.25	-0.50	26.03	-15.82	-12.11	-5.36	-17.89
Net Income	-48.83	-160.28	-137.46	-77.33	7.03	-33.23	-95.30
Net Income - Continuous Operations	-48.83	-160.28	-137.46	-77.33	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-35.57	-149.13	-97.60	-84.78	-34.97	-17.62	-95.15
EBIT	-42.40	-150.89	-99.10	-85.60	-36.66	-26.10	-102.58
Depreciation & Amortization	2.68	1.77	1.49	0.82	1.69	0.82	6.62
Earnings Per Share
Basic EPS	-1.00	-2.00	-2.00	-1.00	-	-1.00	-3.00
Diluted EPS	-1.00	-2.00	-2.00	-1.00	-	-1.00	-3.00
Basic Shares Outstanding	95.14	80.17	60.09	58.54	53.00	37.40	37.33
Diluted Shares Outstanding	95.14	80.17	60.09	58.54	54.94	37.40	37.33